

An evaluation of the prebiotic potential of microbial levans from Erwinia sp. 10119

Article

Accepted Version

Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0

Liu, C., Kolida, S., Charalampopoulos, D. ORCID:
<https://orcid.org/0000-0003-1269-8402> and Rastall, R. A.
(2020) An evaluation of the prebiotic potential of microbial
levans from Erwinia sp. 10119. Journal of Functional Foods,
64. 103668. ISSN 1756-4646 doi:
<https://doi.org/10.1016/j.jff.2019.103668> Available at
<https://centaur.reading.ac.uk/88977/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1016/j.jff.2019.103668>

Publisher: Elsevier

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

1 **An evaluation of the prebiotic potential of microbial levans from *Erwinia***
2 **sp. 10119**

3 Chenxi Liu^{a,1}, Sofia Kolida^a, Dimitris Charalampopoulos^a and Robert A. Rastall^{a,*}

4 ^a Department of Food and Nutritional Sciences, University of Reading, Whiteknights, PO
5 Box 226, Reading, RG6 6AP, UK

6

7 **Abstract**

8 Levan, a bacterial exopolysaccharide, has been suggested to have several biological activities,
9 such as anti-tumour activity and lowering blood pressure. There is also interest in its potential
10 prebiotic activity. This study investigated the fermentation profile of a levan fraction from
11 *Erwinia* sp. 10119 (average DP =137) throughout a three-stage continuous gut model system,
12 in which inulin HP (average DP = 40) was included as a comparison. Levan-type fructan was
13 found to selectively stimulate the growth of *Bifidobacterium* and *Eubacterium rectale* -
14 *Clostridium coccooides* group in all fermenter vessels, with significant ($p<0.05$) increases in
15 the concentration of both acetate and butyrate. The increases in *Bifidobacterium* population
16 were significantly ($p<0.05$) higher in the models treated with levan-type fructan (0.8 to 1.24
17 log cell/mL) compared to the models treated with inulin HP (0.62-0.7 log cell/mL), indicating

Abbreviations: EPS, exopolysaccharide; DP, degree of polymerisation; inulin HP, high performance inulin; Mn, number average molecular weight; Mw, weight average molecular weight; PDI, polydispersity index; SCFA, short chain fatty acid; FOS, fructooligosaccharide; SOD, superoxide dismutase; CAT, catalase; FISH, fluorescent in situ hybridization; OD, optical density; NMR, **nuclear magnetic resonance**; BCA, bicinchoninic acid; BSA, bovine serum albumin; SS1, steady state 1; SS2, steady state 2; DAPI, 6-diamidino-2-phenylindole dihydrochloride; TSP, 3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt; MW, molecular weight.

* Corresponding author. Tel: Tel. +44 (0) 118 378 6726; Fax. +44 (0) 1189310080

E-mail address: r.a.rastall@reading.ac.uk (Robert A. Rastall)

¹ Present address: Henan University of Technology, Zhengzhou, China, 450000

18 a stronger bifidogenic effect of levan-type fructan and a prolonged persistence in the colon
19 due to its higher DP.

20 Key words: exopolysaccharide (EPS), short chain fatty acid (SCFA), gut model, gut
21 microbiota.

22

23 **1. Introduction**

24 A dietary prebiotic is “a selectively fermented ingredient that results in specific changes, in
25 the composition and/or activity of the gastrointestinal microbiota, thus conferring benefit(s)
26 upon host health” (Gibson et al 2010). Various potential beneficial effects of prebiotics have
27 been studied including, control of intestinal transit time and bowel habit, and reduction of risk
28 of atherosclerosis, osteoporosis, obesity, type-2 diabetes, cancer, infections and allergies
29 (Laparra and Sanz, 2010). The establishment of a prebiotic effect requires appropriate
30 nutritional feeding trials with defined health outcomes (Gibson et al., 2010). Short chain fatty
31 acids (SCFAs), the principle end products of microbial metabolism, can activate G-coupled-
32 receptors, inhibit histone deacetylases, and serve as energy sources, hence affect various
33 physiological processes and may contribute to health and disease (Koh et al., 2016). Human
34 studies, however, are not suitable for evaluating the impact on the metabolism of the
35 microbiota as SCFAs are largely absorbed from the colon (Verbeke et al., 2015). To obtain
36 data on faecal metabolism, *in vitro* gut models can be appropriate model systems.

37

38 Many common diseases associated with the human large intestine, such as colon cancer and
39 ulcerative colitis, arise in the distal colon where proteolytic fermentation predominates and
40 potentially toxic metabolites e.g. ammonia, hydrogen sulphide, and cresol are produced

41 (Andriamihaja, et al., 2015; De Preter et al., 2007; Hughes, et al., 2008; Gibson, 2004;
42 McBurney et al., 1987; Ijssennagger, et al., 2016; Oliphant & Allen-Vercoe, 2019).
43 Consequently, there is interest in designing novel prebiotics targeting the distal region of the
44 colon in order to reduce the products of protein metabolism and to increase saccharolytic
45 activity which results in short chain fatty acids. As suggested by a number of studies
46 comparing the fermentation of FOS and inulin in continuous *in vitro* model systems
47 (Rumessen et al., 1990; Van de Wiele et al., 2007) and *in vivo* animal or human trials
48 (Costabile et al., 2010; Patterson et al., 2010; Tuohy et al., 2001), FOS (low DP) are rapidly
49 fermented in the proximal colon, while inulin (high DP) appears to have a more sustainable
50 fermentation through the gut and hence may provide more functional effects in the distal
51 colon. It is clear that there is a positive relationship between DP and the persistence of
52 prebiotics in the gut.

53

54 Inulin and levan are two main types of fructans. Inulin-type fructan consists of linear (2-1)
55 linked β -D-fructosyl units attached to the fructosyl moiety of sucrose, with DP ranging from
56 2 to 60. Inulin has been widely used as a prebiotic, fat replacer, sugar replacer, and texture
57 modifier due to its versatile physicochemical properties and beneficial role in gastric health
58 (Shoaib et al., 2016). Industrial production of inulin has been achieved by extraction from
59 inulin containing plants, such as Jerusalem artichoke and chicory, whereas inulin from
60 microbial sources are less well studied (Ahmed and Rashid, 2017). Levan-type fructan is
61 linked by β (2-6) linkages with occasional β (2-1) branching. Compared with inulin, only a
62 small amount of levan is synthesised in plants by the action of sucrose:sucrose 6
63 fructosyltransferases (6-SST) and some other fructosyltransferases with relatively small
64 chains (DP <10 to 100) (Öner et al., 2016). Bacterial levans on the contrary, are produced
65 from sucrose by transfructosylation with levansucrase, and many are in the range of DP 5000

66 to 50000 depending on the bacteria and culture conditions (Ortiz-Soto et al., 2019). Levan
67 has been marketed in both Korea and Japan, with several claimed health benefits, for
68 example, inhibiting hyperglycaemia and oxidative stress induced by diabetes (Dahech et al.,
69 2011), exhibiting anti-tumour activity against typical tumour cell lines (Abdel-Fattah et al.,
70 2012; Calazans et al., 2000; Esawy et al., 2013; Yoon et al., 2004) and increasing superoxide
71 dismutase (SOD) and catalase (CAT) in the heart (Abdel-Fattah et al., 2012; Dahech et al.,
72 2013). However, these health claims need to be substantiated by more reliable *in vivo* studies.
73 In addition to these potential activities, bacterial strains of several genera were shown to grow
74 on levan or levan-derived FOS, i.e. *Bacteroides* (Adamberg et al., 2014; Sonnenburg et al.,
75 2010), *Lactobacillus* (Martel et al., 2010; Yong et al., 2007), *Bifidobacterium* (Porras-
76 Dominguez et al., 2014). Several levan degrading enzymes have also been identified in gut
77 microbes. A fructofuranosidase from *Bifidobacterium longum* subsp. *Infantis* was found
78 acting on structurally diverse fructans (Ávila-Fernández et al., 2016). An endo-levanase
79 (BT1760) from *Bacteroides thetaiotaomicron*, an abundant commensal gut bacterium, has
80 been biochemically studied (Mardo et al., 2017; Sonnenburg et al., 2010). More recently, the
81 crystal structure of BT1760 was presented by Ernits et al. (2019). The prebiotic potential of
82 levan-type fructans has been studied by some researchers mainly using *in vitro* model
83 systems or animals (Adamberg et al., 2018; Bello et al., 2001; Hamdy et al., 2018; Kang et
84 al., 2000; Marx et al., 2000). However, results have not been consistent due to the use of
85 different model systems and the various origins of levan-type fructans used in these studies.
86 Adamberg et al (2018) documented that the growth of *Collinsella* (Actinobacteria) was
87 enhanced at cultivation of faecal inocula on levans. However, utilisation of levans by bacteria
88 belong to this genus can be hardly evaluated as the majority of this genus are currently
89 uncultured (Almedida et al., 2019). On the other hand, there could be a numerous population
90 of uncultivated gut bacteria that may respond to presence of levan-type fructan. Therefore,

91 the shifts in gut microbe composition brought by supplementation of levan-type fructans
92 remain to be fully revealed.

93

94 In order to evaluate the fermentation profile and gut persistence of long-chain levan-type
95 fructan, this study was carried out using a pH controlled, three-stage continuous gut model
96 mimicking the different regions of the human large intestine. The effects on growth and
97 activity of gut microbiota were analysed by fluorescent *in situ* hybridization (FISH) and high
98 performance liquid chromatography (HPLC).

99

100 **2. Materials and Methods**

101 2.1 Fermentation, fractionation and purification of levan

102 2.1.1 Fermentation

103 Media suitable for levan production were prepared by adding 23 % w/v sucrose into 100 mL
104 Nutrient Broth No.2 (Oxoid) in baffled flasks (Sigma), followed by autoclaving at 121°C for
105 15 min. *Erwinia* sp.10119, isolated from cherry tree gum, was purchased from the National
106 Collections of Industrial, Marine and Food Bacteria (NCIMB). A single colony of *Erwinia*
107 sp. 10119 from a 48 h pre-inoculated agar plate was incubated in 30 mL Sterilin bottles
108 containing 10 mL Nutrient Broth overnight. This pre-incubated cell suspension was then
109 added into 100 mL levan producing media to achieve a starting optical density (OD at 600
110 nm) of 0.05. Flasks containing the inoculated media were incubated at 25°C on a shaking
111 incubator at a speed of 125 rpm for 72 h.

112

113 After fermentation, the culture solution was diluted 1:3 with deionised water and centrifuged
114 at low speed (2,991 *g*) to spin down most of the bacterial cells. After that, a probe sonicator
115 (Soniprep 150, MSE) was used to apply ultrasound to the supernatant at 1-micron amplitude
116 for up to 15 min to de-aggregate the mixture. This crude liquor was then centrifuged again to
117 completely remove residual bacteria cells. The supernatant was collected and stored in 1L
118 Duran bottles at 4°C for no more than 24 h before next treatment.

119

120 2.1.2 Levan fractionation by acid thermal hydrolysis

121 In order to obtain lower DP *Erwinia* levan as the final product, the crude levan-containing
122 supernatant was subjected to acid-thermal hydrolysis. Prior to hydrolysis, the supernatant was
123 rapidly heated to 70°C by a steamer to minimise uneven heating throughout the container.
124 Acid-thermal hydrolysis was carried out in an oven at 70°C without agitation; 0.1% v/v acetic
125 acid was added into a 1 L Duran bottle containing 900 mL of the crude levan solution for 50
126 min before being stopped by addition of 2M NaOH. The crude hydrolysis liquor was cooled
127 to room temperature and stored at 4°C for no more than 2 days before it was passed through a
128 membrane filtration process.

129

130 2.1.3 Levan purification by membrane filtration

131 Ultrafiltration was carried out using a high pressure test unit (Osmonic Desal, Le Mee sur
132 Saine, France). The unit consisted of a feed tank of 4 L capacity, a piston pump and two
133 stainless steel flow cells with a stainless porous sheet membrane support. These cross flow
134 cells were connected in parallel. Two flat sheet asymmetric thin film composite membranes
135 (GE, Osmonic Desal, Gilson Scientific, Luton, UK) with MWCO of 10 kDa were used.

136 Membranes were cut into circular forms with an area of 81cm². Each new membrane was
137 immersed overnight in 2 L of deionised water to remove any preservatives prior to use.
138 Non-continuous diafiltration by volume reduction was employed, whereby the working feed
139 volume of 3.0 L was concentrated to 1.5 L by removing the permeate, while recycling the
140 retentate to the feed tank at 300 psi pressure. The feed was diluted back to its initial volume
141 with deionised water and the diafiltration was repeated three times to remove more of the low
142 molecular weight material. The purified liquor was then concentrated to 500 mL as further
143 concentration results in insufficient circulation. The cumulative retentate was then
144 precipitated with 3 volumes of ethanol in 250 mL Sterilin bottles and left to precipitate at 4°C
145 overnight. After removal of ethanol, the precipitates were dried in a biosafety cabinet,
146 reconstituted with deionised water, then store at – 80°C for 24 h and freeze dried at -55°C for
147 48 h with a VirTis Bench Top freeze dryer (VirTis Sentry 2.0, SP Scientific, Ipswich, UK),
148 and stored in an airtight container at room temperature for further analysis.

149

150 2.2 Analysis of levan

151 NMR was used to confirm the structure of levan by comparing the ¹H NMR and ¹³C NMR
152 spectra with that of levan purchased from Sigma (extracted from *Erwinia herbicola*). NMR
153 samples were prepared by dissolving freeze dried levan in D₂O (20 mg/mL m/v) and then
154 analysed by Bruker Nanobay 400MHz NMR spectroscopy. One-dimensional ¹H NMR
155 spectra were obtained by applying a zg30 pulse sequence at 400MHz with a 3.9584 sec
156 acquisition time, 1 sec relaxation delay, 8278 Hz spectral width, and 296.2 K temperature.
157 Internal solvent D₂O was used as chemical shift reference ($\delta = 4.79$). One-dimensional ¹³C
158 NMR spectra were obtained by applying a zgpg30 pulse sequence with a 1.3665 sec
159 acquisition time, 1.5 sec relaxation delay, 23980 Hz spectral width, and 295.2 K temperature.

160 3-(trimethylsilyl) propionic-2,2,3,3-d₄ acid sodium salt (TSP) was used as chemical shift
161 reference ($\delta = 0.00$). Analysis of the protein content in the final levan product was carried out
162 by BCA (bicinchoninic acid) protein assay kit (Sigma). Bovine serum albumin (BSA)
163 solutions (50-500 $\mu\text{g/mL}$) were used as standards. The working reagent was prepared by
164 mixing 100 mL of reagent A (a solution containing bicinchoninic acid, sodium carbonate,
165 sodium tartrate and sodium bicarbonate in 0.1N NaOH, pH 11.25) with 2mL of Reagent B
166 (4% (w/v) $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$). 2 mL of the working reagent were added to each Eppendorf
167 containing 0.1 mL of BSA standards or freeze dried levan sample (10g/L). After that, these
168 mixed solutions were incubated at 37 °C for 30 mins. After incubation, the absorbance was
169 read at 562 nm. The apparent molar mass was determined by HPLC-RI (Agilent 1100 series,
170 Winnersh, UK) using a PL aquagel-OH MIXED-H 8 μm size exclusion column (Varian,
171 INC., England) before and after hydrolysis. The column temperature was 30°C and HPLC
172 grade water was used as mobile phase at 0.4 mL/min. Sucrose, glucose, FOS, inulin ST
173 and Dextrans (50-1400kDa) were used as external standards. Size exclusion chromatography
174 was also used to determine retention of desired levan fraction after ultrafiltration.

175

176 2.3 Three-stage continuous culture system

177 A scaled-down version of the three-stage continuous culture simulation of the human colon
178 (Macfarlane et al., 1998) was used to investigate the effect of a hydrolysed levan fraction
179 from *Erwinia* sp. 10119, on the faecal microbiota. The scaled down system was run at the
180 same dilution rate (i.e., a rate at which fresh medium was added) to the conventional gut
181 model when operating at a retention time of 48 h (flow rate of 6.25ml/h). The gut model
182 system includes three glass fermenters simulating conditions in the proximal colon (Vessel 1,
183 80 mL, pH 5.5), transverse (Vessel 2, 100 mL, pH 6.2) and distal colon (Vessel 3, 120 mL

184 pH 6.8) and was fed with a complex medium through a peristaltic pump (Watson-Marlow,
185 Cornwall, UK). The intervention dose used in this study (3 g/day) was selected based on
186 previous human studies (Costabile et al., 2010; Tuohy et al., 2001), 8 g/day and 10 g/day
187 respectively. An average of 9g/day (provides 18 kcal of energy per day) was selected,
188 however, as a scaled-down model was used, containing one-third of the normal medium
189 volume, a value of 3g/day was added to the system (Macfarlane et al., 1998). The entire
190 system, including the medium reservoir, was constantly stirred and maintained in an
191 anaerobic condition by continuously sparging with nitrogen. The pH of each vessel was
192 automatically adjusted using pH controllers (Fermac 260; Electrolab, Tewkesbury, UK) by
193 adding 0.5 N HCL and 0.5 N NaOH. The temperature of the culture was maintained at 37 °C
194 by a circulating water bath. Sterile vessels were filled with pre-sterilized medium containing
195 (per litre): 5 g starch, 5 g peptone water, 5 g tryptone, 4.5 g yeast extract, 4.5 g NaCl, 4.5
196 KCl, 4 g mucin, 3 g casein, 2 g xylan, 2 g arabinogalactan, 1.5 g NaHCO₃, 1.25 g
197 MgSO₄·7H₂O, 1 g guar gum, 1 g inulin (Orafti® ST, Beneo, Tienen, Belgium), 0.8 g cysteine-
198 HCl, 0.5 g KH₂PO₄, 0.5 g K₂HPO₄, 0.4 g bile salts, 0.15 g CaCl₂·6H₂O, 0.005 g FeSO₄, 0.05
199 g haemin, 1 mL Tween 80, 0.01 mL vitamin K and 4 mL resazurin solution (0.25 g/L) as a
200 redox indicator.

201

202 Vessels were inoculated with freshly prepared faecal slurries (20% w/w in PBS). The faecal
203 slurries were prepared in strainer stomacher bags (Seward, UK) to remove large particles and
204 were homogenised in a stomacher (Stomacher 400; Seward, West Sussex, UK) for 2 min at
205 medium speed. Faecal samples from three healthy adults were used, each of them was used to
206 inoculate two gut models (one for levan and one for inulin HP). Volunteer selection was
207 based on three criteria, i.e., generally healthy without any current medication; should not

208 have taken any antibiotics or pro/pre-biotic tablets over the last 6 months, should not be a
209 frequent consumer of pro/prebiotic containing food or beverages.

210

211 For each donor, two gut models were inoculated in parallel, 28.6 mL (V1), 33.3 mL (V2), and
212 37.5 mL (V3) were inoculated into culture medium (51.4 mL (V1), 66.7 mL (V2), 82.5 mL
213 (V3)). The systems were run as batch cultures for the first 24 h after inoculation to stabilise
214 the bacterial populations. After this, all the vessels were connected and the medium flow was
215 initiated until eight full volume turnovers (16 days) were completed (steady state 1, SS1). 5
216 mL of sample were taken from each vessel on 3 consecutive days for analysis of bacterial
217 populations and SCFA accumulation. Once stable organic acid profiles were obtained, 3 g of
218 hydrolysed levan or inulin HP (Orafti® HP, Beneo, Tienen, Belgium) were added into vessel
219 1 of the respective gut models on a daily basis for another eight turnovers (16 days), until
220 stable organic acid profiles were observed from samples taken on 3 consecutive days (steady
221 state 2, SS2).

222

223 2.4 Bacterial enumeration

224 Bacterial groups were enumerated using fluorescent *in situ* hybridization (FISH) with 16S
225 rRNA oligonucleotide probes (Table 1). The probes were labelled with the fluorescent Cy3
226 dye as described by Sarbini et al. (2011). Samples (375 mL) were fixed for 4 h at 4° C with
227 4% (w/v) filtered paraformaldehyde (pH 7.2) in a ratio of 1:4 (v/v), washed twice with
228 filtered PBS (0.22 µm pore size), and resuspended in 300 mL of a PBS–ethanol mixture (1:1,
229 v/v). Prior to hybridization, samples were diluted to appropriate concentration and 20 µl of
230 each sample were pipetted onto Teflon- and poly-L-lysine-coated, six-well (10 mm diameter
231 each) slides (Tekdon Inc., Myakka City, FL, USA). In order to make the cells permeable to

232 the hybridization buffer, the slides were dried in a bench top oven at 50°C for 15 min before
233 being finally dehydrated in an ethanol series (50 %, 80 % and 96 % (v/v) ethanol, 3 min
234 each). Fifty microliters of hybridization buffer (containing 5 ng probe /mL) were applied onto
235 the surface of each well. Hybridizations were performed for 4 h in an ISO20 oven (Grant
236 Boekel, Cambridge, UK). Hybridization temperatures for each probe are listed in Table 1.
237 For the washing step, slides were placed in 50 mL of pre-warmed wash buffer containing 20
238 µl of 4, 6-diamidino-2-phenylindole dihydrochloride (DAPI; 50 ng/mL; Sigma, St Louis,
239 MO, USA) for 15 min. They were then washed (2–3 s) in ice-cold water and dried under a
240 stream of compressed air. After that, 5 µl of antifade reagent (polyvinyl alcohol mounting
241 medium with DABCOe antifade, Sigma) were added to each well and a coverslip was
242 applied. Slides were stored in the dark at 4° C until cells were counted under a Nikon E400
243 Eclipse microscope (Nikon, Kingston upon Thames Surrey, UK). Slides were counted within
244 a week, but could be kept for up to three months due to the use of antifading agents. DAPI
245 slides were visualised with the aid of a DM 400 filter and probe slides with the aid of a DM
246 575 filter. Fifteen fields of view were geometrically picked and counted. The average counts
247 were calculated and used for statistical analysis.

248

249 2.5 Short chain fatty acid (SCFA) analysis

250 A sample (1 mL) from the gut model vessels was dispensed into 1.5 mL Eppendorf tubes and
251 centrifuged at 13 000 x g for 10 min to sediment bacteria and other solids. Supernatants were
252 filtered using 0.2 µm polycarbonate syringe filters (Whatman International Ltd, Maidstone,
253 Kent, UK) and injected with internal standard (diethylbutyric acid, Sigma) at a ratio of 4:1
254 into an HPLC system (Merck, Whitehouse Station, NJ, USA) equipped with refractive index
255 (RI) detection. The column used was an ion-exclusion REZEX ROA organic acid column

256 (Phenomenex, Inc., Macclesfield, Cheshire, UK) maintained at 85°C. Sulfuric acid in HPLC-
257 grade water (0.0025M) was used as the eluent and the flow rate was maintained at 0.5
258 mL/min. The carboxylic acids in the samples were quantified using calibration curves of
259 acetic, propionic, butyric, valeric and formic acid, in concentrations ranging between 2.5 and
260 100 mM.

Table 1 Oligonucleotide probes and hybridisation conditions used in this study

Probe name	Sequence (5' to 3')	Bacterial groups enumerated	Hybridization pre-treatment	Formamide (%) in hybridization buffer	Temperature (°C)		Reference
					Hybridization	Washing	
Ato291	GGTCGGTCTCTCAACCC	<i>Atopobium</i> group	None	0	50	50	Harmsen et al. (2000)
Bac303	CCAATGTGGGGACCTT	<i>Bacteroides/ Prevotella</i>	None	0	46	48	Manz et al. (1996)
Bif164	CATCCGGCATTACCACCC	<i>Bifidobacterium</i> spp.	None	0	50	50	Langendijk et al. (1995)
Chis150	TTATGCGGTATTAATCTYCCTTT	<i>Clostridium histolyticum</i> group	None	0	50	50	Franks et al. (1998)
Prop853	ATTGCGTAACTCCGGCAC	<i>Clostridium</i> cluster IX	None	0	50	50	Walker et al. (2005)
Erec482	GCTTCTTAGTCARGTACCG	<i>Eubacterium rectale-Clostridium coccoides</i> group	None	0	50	50	Franks et al. (1998)
Lab158	GGTATTAGCAYCTGTTTCCA	<i>Lactobacillus-Enterococcus</i> spp.	Lysozyme	0	50	50	Harmsen et al. (1999)
Rrec584	TCAGACTTGCCGYACCGC	<i>Roseburia</i> spp.	None	0	50	50	Walker et al. (2005)
Frpau655	CGCCTACCTCTGCACTAC	<i>Faecalibacterium prausnitzii</i> group	None	0	58	58	Hold et al. (2003)
EUB338‡	GCTGCCTCCCGTAGGAGT	Total bacteria	None	35	46	48	Daims et al. (1999)
EUB338II‡	GCAGCCACCCGTAGGTGT	(mixed EUB338 probes)	None	35	46	48	Daims et al. (1999)
EUB338III‡	GCTGCCACCCGTAGGTGT		None	35	46	48	Daims et al. (1999)

262 2.6 Statistical analysis

263 Statistical analysis was performed using SPSS for Windows, Version 18.0. A paired
264 independent t-test was used to determine significant changes for each bacterial group and
265 SCFA concentration between steady state 1 (SS1) of faecal fermentation without adding test
266 substrate and steady state 2 (SS2) after adding the test substrate. One-way analysis of
267 variance (ANOVA) and Tukey's posthoc test were used to determine significant differences
268 in bacterial group populations and SCFA concentrations among the different volunteers.
269 Differences were considered to be significant when $p < 0.05$.

270

271 **3. Results and Discussion**

272 3.1 Levan characterization

273 Comparison of the chemical shifts in ^{13}C NMR and ^1H NMR spectrum of levan produced in
274 this experiment with that for Sigma levan reveals the $[\rightarrow 6)\text{-}\beta\text{-D-Fruf-(2}\rightarrow)]_n$ main chain
275 structure of produced levan. Chemical shifts were shown in Table 2. Residual protein was
276 non-detectable in the final product. The result of size exclusion chromatography showed that
277 the molecular mass of natural levan produced by *Erwinia* sp. 10119 was about DP 7719 (1.3
278 $\times 10^6$ Daltons), which is comparable to the previous reported molecular range weight of levan
279 produced from *Erwinia herbicola* (1.1×10^6 - 1.6×10^6 Daltons) (Keith et al., 1991). After acid-
280 thermal hydrolysis, the molecular mass of resulting levan fraction was examined again by
281 size exclusion chromatography. The molecular weight distribution of obtained levan fraction
282 was illustrated in Fig.1. The hydrolysed levan fraction had a weight average molecular
283 weight (Mw) of approximately 22220 g mol^{-1} (DP = 137) and a dispersity of 5.75. Membrane
284 processing resulted in a moderate DP levan fraction with 15 % (w/w) of mono- and oligo-
285 saccharides. The results are expressed as mass percentages of the compounds left after


286 ultrafiltration based on GPC area measurements. Overall, the type of linkage, DP and purity
 287 of levan fractions produced by the present used method, consisting of centrifugation,
 288 sonication, acid-thermal hydrolysis and ethanol precipitation were found satisfactory, and
 289 these fractions could be subjected to the three-stage gut model for further evaluation of their
 290 prebiotic potential and gut persistency.

291 **Table 2 Comparison of ¹H and ¹³C NMR data of lavean produced in this study with Sigma**
 292 **Levan (*Erwinia herbicola*) and chemical shifts data published for levan from *Bacillus* sp. 3B6**
 293 **and *Zymomonas mobilis* (Angeli et al., 2009, Matulová et al., 2011)**

Compound	¹ H and/or ¹³ C chemical shifts /δ							
		1, 1'	2	3	4	5	6, 6'	
Levan (<i>Erwinia</i> sp. 10119)	H	3.644 3.570	-	4.066	3.982	3.836	3.775	3.437
	C	59.79	103.79	76.19	75.11	80.24	63.33	
Levan (Sigma- <i>Erwinia herbicola</i>)	H	3.645 3.571	-	4.067	3.984	3.838	3.775	3.440
	C	59.81	103.78	76.21	75.13	80.24	63.33	
Levan (<i>Bacillus</i> sp. 3B6)	H	3.77 3.670	-	4.178	4.096	3.958	3.898	3.549
	C	60.75	105	77.15	76	81.07	64.2	
Levan (<i>Zymomonas mobilis</i>)	H	3.8 3.7	-	4.3	4.2	4.0	3.85	3.55
	C	61.4	105.1	77.5	76.6	81.3	64.6	

294

295



296

297 **Fig.1. Molecular weight distribution of hydrolysed levan analysed by Size exclusion**

298 **chromatography (n=3).** Mn, number average molecular weight; Mw, weight average molecular weight;

299 Dispersity= Mw/Mn.

300

301 3.2 Changes in microbiota composition upon inulin and levan supplementation

302 The work presented here is the first to evaluate the fermentation selectivity of levan-type

303 fructan in a continuous gut model system. Fig. 2 shows the bacterial concentrations before

304 (SS1) and after (SS2) the addition of test substrates. The mean values for each probe are

305 averages of three volunteers for each substrate (inulin HP and levan-type fructan) in each

306 vessel (V1, V2 and V3) representing different regions of the colon, i.e. proximal, transverse

307 and distal colon. Significant stimulation ($p < 0.05$) of *Bifidobacterium* was observed for both

308 test substrates in all vessels, which is in line with results from Tuohy et al. (2001), who

309 reported a stimulation of *Bifidobacterium* after an *in vivo* inulin HP intervention (8g/ day). In

310 comparison, using a five-stage *in vitro* continuous Simulator of the Human Intestinal

311 Microbial Ecosystem (SHIME), Van de Wiele et al. (2004) only observed an increase of

312 *Bifidobacterium* in vessel 1 (proximal colon) when natural chicory inulin (average DP <10)

313 was used as a supplement at a dose equal to 5 g/day. Furthermore, the population of
314 *Bifidobacterium* was significantly higher in all three vessels in the models treated with levan
315 than with inulin HP, exhibiting a stronger bifidogenic effect of levan. This is supported by
316 Ávila-Fernández et al. (2016), who found that a β -fructofuranosidase from *Bifidobacterium*
317 *longum* subsp. *infantis* ATCC 15697 has higher affinity for levan-type than inulin-type FOS.
318 No significant changes were observed in population of *Lactobacillus-Enterococcus* for both
319 substrates. This is in line with the results of Tuohy et al. (2002) and Harmsen et al. (2002), in
320 which these groups of bacteria were unaffected by supplementation with inulin HP.

321

322 A decrease in *Bacteroides - Prevotella* (ranging from 0.1 to 0.86 log cells/mL) was observed
323 when inulin HP was added, while there were no significant changes in the levan models.
324 Harmsen et al., (2002) has reported similar results in a human study on inulin in which 10
325 healthy volunteers were given inulin HP for 14 days at a dose of 9 g/day. Inulin HP did not
326 have any significant stimulation effect on the *Bacteroides – Prevotella* group, and a decrease
327 of 0.6 log cells/mL has been observed during the treatment. The decrease in number of
328 *Bacteroides* was also reported by two other studies evaluating the prebiotic potential of high
329 molecular weight inulin by human studies (Costabile et al. 2010; Tuohy et al. 2002).
330 Moreover, Sonnenburg et al. (2010) showed that many studied *Bacteroides* species (for
331 example *B. thetaiotaomicron* and *B. vulgatus*) did not grow on inulin. (Sonnenburg et al.,
332 2010).

333

334 Varied responses to inulin and levan were found for different groups of *Clostridium*, including
335 commensal (*Eubacterium rectale- Clostridium coccoides* groups, *Clostridium* cluster IX,
336 *Roseburia* spp. and *Faecalibacterium prausnitzii*) and pathogenic species (*Clostridium*

337 *histolyticum*). Significant stimulation ($p < 0.05$) of *Eubacterium rectale*- *Clostridium*
338 *coccoides* groups was observed for both test substrates in all vessels, and populations of this
339 group of bacteria were significantly higher in all three vessels in the models treated with
340 levan than with inulin HP. Significant increase in population of *Roseburia* was observed in
341 all vessels treated with both substrates. A different result has been reported by Ramirez-
342 Farias et al. (2008) that no significant increase was found in number of *Roseburia* after inulin
343 supplementation as a mean of all volunteers. However, they also documented a strong
344 increase upon inulin ingestion of two volunteers and suggested a possible variance between
345 volunteers in which different strain/species of *Roseburia* were present (Ramirez-Farias et al.,
346 2008). This assumption was then supported by Sheridan et al. (2016), who found that all
347 tested *R. inulinivorans* strains were capable of utilizing inulin, whereas *R. intestinalis*, *R.*
348 *hominis* and *R. faecis* strains did not grow on inulin as the sole carbohydrate source (Sheridan
349 et al., 2016). *Clostridium* cluster IX also showed a significant decrease (ranging from 0.34 to
350 0.73 log cells/mL) in all vessels treated with both substrates. A similar finding has been
351 reported by Van de Wiele et al. (2006), in which the numbers of clostridia decreased after
352 intervention with inulin HP using SHIME model at a dose of 2.5 g/day. The population of
353 *Faecalibacterium prausnitzii*, significantly decreased in the models with added inulin HP in
354 all three vessels (0.57 log cells/mL decrease in V1, 0.44 log cells/mL decrease in V2 and 0.3
355 log cells/mL decrease in V3), while the addition of levan-type fructan led to an increase in
356 vessel 2 (0.25 log cells/mL), after a decrease in vessel 1 (0.61 log cells/mL), also suggesting a
357 transit-dependent effect. In contrast to the present study, many researchers have documented
358 stimulative effects of inulin on the population of *F. prausnitzii* (Lopez-Siles et al., 2017;
359 Ramirez-Farias et al., 2008). Besides, Kleessen et al. (2007) reported that no significant
360 change was observed in *F. prausnitzii* counts in volunteers consumed snack bars containing
361 inulin (7.7 g/d) after a 7-d run-in period. However, Moens and De Vuyst (2017) studied the

362 utilisation of inulin by *F. prausnitzii* in pure cultures and suggested that *F. prausnitzii* could
363 degrade both FOS and inulin. Moreover, Moen et al. (2016) documented that a cross-feeding
364 interactions between bifidobacteria and acetate-depending, butyrate-producing *F. prausnitzii*
365 was observed and can be either a beneficial relationship or dominated by competition,
366 depending on the inulin degradation capacities of the bifidobacterial strains involved.
367 Therefore, decrease in number of *F. prausnitzii* seen in the present study could be possibly
368 explained by the competition between *F. prausnitzii* and other dominating gut microbes.
369 However, this will have to be confirmed in other intervention studies. In addition, no
370 significant changes were observed for *Clostridium histolyticum*. This is in line with the
371 results of Tuohy et al. (2002) and Harmsen et al. (2002), in which this groups of bacteria
372 were unaffected by supplementation with inulin HP.

373

374 For the *Atopobium* cluster, with addition of inulin HP, no significant increase was observed in
375 the first two vessels, but there was a 0.31 log cells/mL increase in vessel 3, suggesting a
376 stimulation effect in the distal colon. This cluster of bacteria is a dominant member of the
377 faecal microbiota of healthy humans, which making up around 8 % of the microbiota
378 (Thorasin et al., 2015). The result found in the present study is in good agreement with
379 Costabile et al. (2010), who also reported a significant increase of *Atopobium* after 14 days
380 supplementation with inulin. However, no significant difference was obtained with addition
381 of levan-type fructan across all three vessels.

382

383 Briefly, both inulin and levan contributed to beneficial shifts towards the gut microbial
384 composition, indicated by significant increase in population of *Bifidobacterium* spp. Such
385 bifidogenic effect is widely accepted as beneficial to the host health due to the carbohydrate-

386 fermenting pattern of bacteria strains belong to the genus *Bifidobacterium* (Meyer and Stasse-
387 Wolthuis, 2009). Also, a stronger bifidogenic effect of levan-type fructan has been observed.
388 Various groups of commensal bacteria were enumerated and some of them showed different
389 responses between the two types of fructans. The main differences were among the changes
390 in the populations of *the Bacteroides-Prevotella* group, *Atopobium* cluster and *F. prausnitzii*,
391 due to their capacities of using different fructans in the complex gut ecosystem. In addition,
392 no stimulation of pathogenic clostridia (*Clostridium histolyticum*) was observed for both
393 substrates, indicating that no adverse effect on the host health was induced by inulin and
394 levan supplementation in terms of their effects on *Clostridium histolyticum*.







395





396 Compared with inulin, the effect of levan-type fructans on the human gut microbiota has
397 hitherto only been studied using batch cultures. Marx et al. (2000) tested the abilities of
398 various bacterial genera to ferment long chain levan and levan oligosaccharides in pure
399 cultures, including several strains of *Bifidobacterium* and found that only levan
400 oligosaccharides demonstrated an enrichment effect on the tested strains (*B. adolescentis*, *B.*
401 *breve*, *B. longum* and *B. pseudocatenulatum*). In another study, the *in vitro* fermentation
402 properties of a commercial levan from Sigma (originating from *Erwinia herbicola*) and two
403 self-isolated levan-type exopolysaccharides (originating from *Lactobacillus sanfranciscensis*)
404 were studied using human faeces as an inoculum (Bello et al., 2001). An enrichment of
405 *Bifidobacterium* species was found with the levan type exopolysaccharides produced by
406 *Lactobacillus sanfranciscensis*, but not for levan from *Erwinia herbicola*. Levan synthesized
407 using levansucrase from *Pseudomonas syringae* was found to act as an easily degradable
408 substrate for *Bacteroides thetaiotaomicron* when tested with pure culture (Adamberg et al.,
409 2014). Mardo et al. (2017) reported that the endo-levanase from *B. thetaiotaomicron* can
410 degrade various β -2, 6-linked polyfructan levans. They also suggested that the long chain

411 levan molecules were degraded into FOS with a cell surface bound endo-levanase BT1760,
412 and the FOS was then consumed by *B. thetaiotaomicron* and other gut bacteria, including
413 health-promoting bifidobacteria and lactobacilli (Mardo et al., 2017). Such cross-feeding
414 effect was previously documented by Rakoff-Nahoum et al. (2014), who reported that
415 fructose and oligosaccharides liberated from levan metabolized by *B. thetaiotaomicron* could
416 support the growth of Bacteroidales species without levan utilising ability. Crystal structure
417 of the BT1760 supported this assumption once again (Ernits et al., 2019). Hamdy et al.
418 (2018) investigated the prebiotic activity of *Bacillus* levan in rat feeding trails. They found
419 that levans produced by two strains of *Bacillus subtilis* (HMNig-2 and MENO2) both have
420 the ability of lowing coliform count and increasing lactobacillus count in gut especially when
421 used together with the probiotic strain *B. subtilis* HMNig-2 and MENO2. More recently,
422 both natural levan from *Erwinia herbicola*, and a low molecular weight (8 kDa), highly
423 branched levan from *Bacillus amyloliquefaciens* JN4 were shown to exhibit antiadhesive
424 activity against enterotoxigenic *Escherichia coli*, whereas such activity was not found with
425 chicory inulin (Cai et al., 2019) The fermentation of levanheptaose on some components of
426 the intestinal microbiota was studied by Kang et al (2000) using pure cultures. Growth of
427 *Bifidobacterium adolescentis*, *Lactobacillus acidophilus* and *Eubacterium limosum* were
428 stimulated, whereas numbers of *Clostridium perfringens*, *E. coli* and *Staphylococcus aureus*
429 remain unchanged compared with control cultures. Kang et al (2000) also studied the effect
430 of levanheptaose on the gut microbiota of rats. The ingestion of levanheptaose resulted in a 1
431 log cell/ mL increase in the faecal counts of endogenous bifidobacteria, without affecting
432 *Lactobacillus* sp. The amount of butyrate as well as β -fructosidase activity were increased,
433 whereas pH was reduced in rats fed levanheptaose diets as compared to those on the control
434 diet (Kang et al., 2000).

435

436 The molecular weight of a fructan has an effect on the fermentation behaviour (Biedrzycka
437 and Bielecka, 2004). The results of *in vitro* studies using pure cultures indicate the specificity
438 for *Bifidobacterium* spp., with the exception of *B. bifidum*, when utilising short chain
439 fructooligosaccharides and inulins of average DP over 9, but not highly polymerized inulins
440 (average DP = 40). The results of subsequent *in vivo* studies on rats also suggested the
441 selectivity of fructooligosaccharides and low DP inulins, for *Bifidobacterium* spp., while the
442 effects of highly polymerized inulin were more diverse and related to the presence and ability
443 of other bacteria to initiate degradation (Biedrzycka and Bielecka, 2004). On the other hand,
444 degree of branching also has effects on the fermentation property of levan. Although this
445 effect has not been fully understood, Yoon et al. (2004) found that anti-tumour activity of
446 levan towards SNU-1 and HepG2 tumour cell lines decreased rapidly as the degree of
447 branching reduced. Also, Benigar et al. (2014) found that levan from three different origins
448 (i.e. *Bacillus subtilis*, *Zymomonas mobilis*, and *Erwinia herbicola*) differed in their structural
449 and dynamic properties in aqueous solutions. Their Small-Angle X-ray Scattering result
450 indicated that, in aqueous solution, *Bacillus subtilis* levan was the least entangled with the
451 most flexible structure while *Erwinia herbicola* levan was the most entangled, reflected in
452 higher solution turbidity at the same concentration (Beinigar et al., 2014). Factors affecting
453 the particle-forming property were mainly MW and branching of levan molecules.
454 Furthermore, as reported by Bello et al. (2001), a bifidogenic effect was not found with
455 natural *Erwinia herbicola* levan compared with levan from other sources, we hypothesised
456 that this particle-forming property could possibly limit the contact between digestion
457 enzymes of gut bacteria and natural levan molecules and hence restrict their bioactivity. In
458 the current study, after acid hydrolysis, turbidity of levan solution was reduced to a great
459 extent and the hydrolysed levan (DP =137) showed enhanced prebiotic potential comparing
460 with inulin HP as well as a gut persistence given by large molecular weight.





462

463

464 **Fig. 2. Mean bacterial populations (log₁₀ cell per mL) in each vessel of the three-stage continuous system (vessel 1, 2 and 3) at steady state 1 and steady state**
 465 **2.** Standard deviation is shown in parentheses with n=3. *denoted a significant change in bacterial number in SS2 compared to SS1 at P < 0.05; ** denoted a
 466 significant change in bacterial number in SS2 compared to SS1 at P < 0.01. SS1: Steady state 1, fermentation without adding test substrate; SS2: steady state 2, after
 467 adding the test substrate.


468 3.3 Short chain fatty acid production

469 Changes in SCFA concentrations are shown in Fig. 3. In the gut model system, SCFA
470 accumulate across all three vessels, which is not physiological so only changes in vessel will
471 be discussed here. Acetate, butyrate, and propionate were the three main SCFAs
472 accumulating during fermentation. The concentration of acetate significantly ($p < 0.05$)
473 increased in all three vessels for both test substrates ranging from 14.16 mM to 30.37 mM,
474 while both inulin HP and levan-type fructan led to a large increase in vessel 1 (30.37mM and
475 29.74 mM, respectively), with no significant differences between them. This is consistent
476 with the changes in number of *Bifidobacterium* spp., which is known as a lactate and acetate
477 producer. Lactate was not detected in any vessel due to consumption by butyrate producing
478 bacteria such as *Clostridium* cluster IV (e.g. *Faecalibacterium prausnitzii* group and
479 *Eubacterium rectale- Clostridium coccoides* group) and XIVa (e.g. *Roseburia* spp.).
480 Accordingly, the butyrate concentration also increased significantly after the intervention,
481 both substrates giving rise to significant increases ranging from 26.03 mM to 65.41mM, in
482 line with the increase in number of *Clostridium* cluster IV and XIVa. Enrichment in acetate
483 and butyrate production has been reported by many inulin intervention studies (Alexander et
484 al., 2018; Thøgersen et al., 2018; van der Beek et al., 2018). Moreover, similar result has been
485 documented regarding levan-type fructan. Adamberg et al. (2018) found that administration
486 of levan corrected the metabolic pattern of overweight children faecal consortium by
487 increasing the production of butyrate and acetate. Besides, as the concentration of acetate and
488 butyrate increased, the accumulation of propionate significantly decreased after addition of
489 inulin HP while treatment with levan-type fructan did not affect the propionate concentration
490 significantly. This is the main difference between SCFAs production induced by
491 supplementation of two tested substrates and is consistent with the changes in number of
492 *Bacteroides – Prevotella*, which is known as an acetate, lactate, and propionate producer.

493 Total organic acids also significantly increased in all vessels. There was no significant
494 difference between the test substrates.

495

496 Overall, a possible route of levan metabolism was proposed based on the experimental data
497 of the present study and information from the literature. Levans are firstly degraded by
498 *Bifidobacterium*, *Bacteroides*, and *Lactobacillus* to produce fructose, FOS and organic acids,
499 especially lactate and acetate. The hydrolysis products and SCFAs are then utilized by
500 butyrate-producing bacteria (such as *Eubacterium*, *Faealibacterium* and *Roseburia*) and other
501 nondegraders of levans with the production of butyrate and other metabolic products.



502

503 **Fig. 3 Mean short chain fatty acid concentration (mM) in each vessel of the three-stage continuous system (vessel 1, 2 and 3) at steady state 1 and**
 504 **steady state 2**, Standard deviation is shown in parentheses with n=3. *denoted a significant change in bacterial number in SS2 compared to SS1 at P < 0.05; ** denoted a
 505 significant change in bacterial number in SS2 compared to SS1 at P < 0.01. SS1: Steady state 1, fermentation without adding test substrate; SS2: steady state 2, after
 506 adding the test substrate.

507 **4. Conclusion**

508 The *in vitro* fermentation of a hydrolysis product of levan (average DP =137), produced from
509 *Erwinia* sp. 10119 was investigated in pH controlled three-stage compound continuous gut
510 model systems compared with inulin HP (average DP = 40). *Bifidobacterium* and
511 *Eubacterium rectale* - *Clostridium coccooides* groups significantly increased in all vessels
512 including the 3rd vessel simulating the distal colon. The increases were significantly higher in
513 the models treated with levan-type fructan (0.8 to 1.24 log cell/mL) compared to the inulin HP
514 models (0.62-0.7 log cell/mL), indicating a stronger bifidogenic effect of levan-type fructan
515 and prolonged persistence in the colon due its higher DP. Both acetate and butyrate
516 significantly increased in all the vessels of the system, although no significant difference was
517 observed between them. The structural differences among levan from different
518 microorganisms have not been determined in this study. However, it has been reported by
519 various researchers that the molecular weight and degree of branching varies among levans
520 from different producers, which most likely results in differences in their fermentation
521 properties. Thus, it would be valuable to evaluate these relationships in well designed *in vitro*
522 and *in vivo* studies with the aim to develop novel prebiotics based on these polymers.

523

524 **Acknowledgement**

525 This research did not receive any specific grant from funding agencies in the public,
526 commercial, or not-for-profit sectors.

527

528

529

530 **References**

- 531 Abdel-Fattah, A. M., Gamal-Eldeen, A. M., Helmy, W. A., & Esawy, M. A. (2012).
532 Antitumor and antioxidant activities of levan and its derivative from the isolate *Bacillus*
533 *subtilis* NRC1aza. *Carbohydrate polymers*, *89*, 314-322.
- 534 Adamberg, K., Adamberg, S., Ernits, K., Larionova, A., Voor, T., Jaagura, M., ... Alamäe, T.
535 (2018). Composition and metabolism of fecal microbiota from normal and overweight
536 children are differentially affected by melibiose, raffinose and raffinose-derived fructans.
537 *Anaerobe*, *52*, 100-110.
- 538 Adamberg, K., Tomson, K., Talve, T., Pudova, K., Puurand, M., & Visnapuu, T. (2015).
539 Levan enhances associated growth of *Bacteroides*, *Escherichia*, *Streptococcus* and
540 *Faecalibacterium* in faecal microbiota. *PLoS One*. *10*, 1-19.
- 541 Adamberg, S., Tomson, K., Vija, H., Puurand, M., Kabanova, N., & Visnapuu, T. (2014).
542 Degradation of Fructans and Production of Propionic Acid by *Bacteroides*
543 *thetaiotaomicron* are Enhanced by the Shortage of Amino Acids. *Frontiers in Nutrition*, *1*,
544 1-10.
- 545 Ahmed, W., & Rashid, S. (2017). Functional and therapeutic potential of inulin: A
546 comprehensive review. *Critical Reviews in Food Science and Nutrition*, *59(1)*, 1-13.
- 547 Almeida, A., Mitchell, A. L., Boland, M., Forster, S. C., Gloor, G. B., Tarkowska,
548 A., ... Finn, R. D., (2019). A new genomic blueprint of the human gut microbiota. *Nature*
549 *568*, 499-504.
- 550 Alexander, C., Cross, T. W. L., Devendran, S., Neumer, F., Theis, S., Ridlon, J. M., ...
551 Swanson, K. S. (2018). Effects of prebiotic inulin-Type fructans on blood metabolite and
552 hormone concentrations and faecal microbiota and metabolites in overweight dogs. *Clay*
553 *Minerals*, *120*, 711-720.
- 554 Andriamihaja, M., Lan, A., Beaumont, M., Audebert, M., Wong, X., Yamada, K., ...
555 Blachier, F. (2015). The deleterious metabolic and genotoxic effects of the bacterial
556 metabolite p-cresol on colonic epithelial cells. *Free Radical Biology and Medicine*, *85*,
557 219-227.
- 558 Ávila-Fernández, Á., Cuevas-Juárez, E., Rodríguez-Alegría, M. E., Olvera, C., & López-
559 Munguía, A. (2016). Functional characterization of a novel β -fructofuranosidase from
560 *Bifidobacterium longum* subsp. *infantis* ATCC 15697 on structurally diverse fructans.
561 *Journal of Applied Microbiology*, *121*, 263-276.
- 562 Bello, D. F., Walter, J., Hertel, C., & Hammes, W. P. (2001). *In vitro* study of prebiotic
563 properties of levan-type exopolysaccharides from lactobacilli and non-digestible
564 carbohydrates using denaturing gradient gel electrophoresis. *Systematic and Applied*
565 *Microbiology*, *24*, 232-237.
- 566 Benigar, E., Dogsa, I., Stopar, D., Jamnik, A., Cigić, I. K., & Tomšič, M. (2014). Structure
567 and dynamics of a polysaccharide matrix: Aqueous solutions of bacterial levan. *Langmuir*,
568 *30(14)*, 4172-4182.
- 569 Biedrzycka, E., & Bielecka, M. (2004). Prebiotic effectiveness of fructans of different degrees
570 of polymerization. *Trends in Food Science & Technology*, *15*, 170-175.

- 571 Cai, G., Liu, Y., Li, X., & Lu, J. (2019). New Levan-Type Exopolysaccharide from *Bacillus*
572 *amyloliquefaciens* as an Antiadhesive Agent against Enterotoxigenic *Escherichia coli*.
573 *Journal of Agricultural and Food Chemistry*, 67(28), 8029–8034.
- 574 Calazans, G. M., Lima, R. C., de França, F. P., & Lopes, C. E. (2000). Molecular weight and
575 antitumour activity of *Zymomonas mobilis* levans. *International Journal of Biological*
576 *Macromolecules*, 27, 245-247.
- 577 Charalampopoulos, D., & Rastall, R. A. (2012). Prebiotics in foods. *Current opinion in*
578 *biotechnology*, 23, 187-191.
- 579 Corradini, C., Bianchi, F., Matteuzzi, D., Amoretti, A., Rossi, M., & Zanoni, S. (2004). High-
580 performance anion-exchange chromatography coupled with pulsed amperometric detection
581 and capillary zone electrophoresis with indirect ultra violet detection as powerful tools to
582 evaluate prebiotic properties of fructooligosaccharides and inulin. *Journal of*
583 *Chromatography A*, 1054, 165-173.
- 584 Costabile, A., Kolida, S., Klinder, A., Gietl, E., Bäuerlein, M., Froberg, C., & Gibson, G. R.
585 (2010). A double-blind, placebo-controlled, cross-over study to establish the bifidogenic
586 effect of a very-long-chain inulin extracted from globe artichoke (*Cynara scolymus*) in
587 healthy human subjects. *British journal of nutrition*, 104, 1007-1017.
- 588 Dahech, I., Belghith, K. S., Hamden, K., Feki, A., Belghith, H., & Mejdoub, H. (2011).
589 Antidiabetic activity of levan polysaccharide in alloxan-induced diabetic
590 rats. *International journal of biological macromolecules*, 49, 742-746.
- 591 Dahech, I., Harrabi, B., Hamden, K., Feki, A., Mejdoub, H., Belghith, H., & Belghith, K. S.
592 (2013). Antioxidant effect of nondigestible levan and its impact on cardiovascular disease
593 and atherosclerosis. *International journal of biological macromolecules*, 58, 281-286.
- 594 Daims, H., Brühl, A., Amann, R., Schleifer, K. H., & Wagner, M. (1999). The Domain-specific
595 Probe EUB338 is Insufficient for the Detection of all Bacteria Development and Evaluation
596 of a more Comprehensive Probe Set. *Systematic and applied microbiology*, 22, 434-444.
- 597 De Preter, V., Vanhoutte, T., Huys, G., Swings, J., De Vuyst, L., Rutgeerts, P., & Verbeke,
598 K. (2007). Effects of *Lactobacillus casei* Shirota, *Bifidobacterium breve*, and
599 oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans.
600 *American Journal of Physiology: Gastrointestinal and Liver Physiology*, 292, 358-368.
- 601 Diplock, A. T., Aggett, P. J., Ashwell, M., Bornet, F., Fern, E. B., & Roberfroid, M. B.
602 (1999). Scientific concepts of functional foods in Europe: consensus document. *British*
603 *Journal of Nutrition*, 81, S1-S27.
- 604 Ernits, K., Eek, P., Lukk, T., Visnapuu, T., & Alamäe, T. (2019). First crystal structure of an
605 endo-levanase - the BT1760 from a human gut commensal *Bacteroides thetaiotaomicron*.
606 *Scientific Reports*, 9(1), 8443.
- 607 Esawy, M. A., Amer, H., Gamal-Eldeen, A. M., El Enshasy, H. A., Helmy, W. A., Abo-Zeid,
608 M. A., & Awad, G. E. (2013). Scaling up, characterization of levan and its inhibitory role
609 in carcinogenesis initiation stage. *Carbohydrate polymers*, 95, 578-587.

- 610 Franks, A. H., Harmsen, H. J., Raangs, G. C., Jansen, G. J., Schut, F., & Welling, G. W. (1998).
611 Variations of bacterial populations in human feces measured by fluorescent *in situ*
612 hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. *Applied and*
613 *Environmental Microbiology*, *64*, 3336-3345.
- 614 Gibson, G.R. 2004. Fibre and effects on probiotics (the prebiotic concept). *Clinical Nutrition*
615 *Supplements*, *1*, 25–31.
- 616 Gibson, G. R., Probert, H. M., Van Loo, J., Rastall, R. A., & Roberfroid, M. B. (2004). Dietary
617 modulation of the human colonic microbiota: updating the concept of prebiotics. *Nutrition*
618 *Research Reviews*, *17*, 259-275.
- 619 Gibson, G. R., Scott, K. P., Rastall, R. A., Tuohy, K. M., Hotchkiss, A., Dubert-Ferrandon, A.,
620 Gareau, M., Murphy, E. F., Saulnier, D., Loh, G., Macfarlane, S., Delzenne, N., Ringel, Y.,
621 Koziowski, G., Dickmann, R., Lenoir-Wijnkook, I., Walker, C., & Buddington, R. (2010).
622 Dietary prebiotics: current status and new definition. *IFIS Functional Foods Bulletin*, *7*, 1-
623 19.
- 624 Gibson, G. R., & Wang, X. (1994). Enrichment of bifidobacteria from human gut contents by
625 oligofructose using continuous culture. *FEMS Microbiology Letters*, *118*, 121-127.
- 626 Hamdy, A. A., Elattal, N. A., Amin, M. A., Ali, A. E., Mansour, N. M., Awad, G. E., Farrag,
627 A. R. H., & Esawy, M. A. (2018). In vivo assessment of possible probiotic properties
628 of *Bacillus subtilis* and prebiotic properties of levan. *Biocatalysis and Agricultural*
629 *Biotechnology*, *13*, 190–197.
- 630 Harmsen, H. J., Elfferich, P., Schut, F., & Welling, G. W. (1999). A 16S rRNA-targeted probe
631 for detection of lactobacilli and enterococci in faecal samples by fluorescent *in situ*
632 hybridization. *Microbial Ecology in Health and Disease*, *11*, 3-12.
- 633 Harmsen, H. J., Raangs, G. C., Franks, A. H., Wildeboer-Veloo, A. C., & Welling, G. W.
634 (2002). The effect of the prebiotic inulin and the probiotic *Bifidobacterium longum* on the
635 faecal microflora of healthy volunteers measured by FISH and DGGE. *Microbial Ecology*
636 *in Health and Disease*, *14*, 212-220.
- 637 Hongpattarakere, T., Cherntong, N., Wichienchot, S., Kolida, S., & Rastall, R. A. (2012). *In*
638 *vitro* prebiotic evaluation of exopolysaccharides produced by marine isolated lactic acid
639 bacteria. *Carbohydrate Polymers*, *87*, 846-852.
- 640 Hughes, R., Kurth, M. J., McGilligan, V., McGlynn, H., & Rowland, I. (2008). Effect of
641 colonic bacterial metabolites on Caco-2 cell paracellular permeability *in vitro*. *Nutrition*
642 *and Cancer*, *60*, 259–66.
- 643 Ijssennagger, N., van der Meer, R., & van Mil, S. W. C. (2016). Sulfide as a Mucus Barrier-
644 Breaker in Inflammatory Bowel Disease? *Trends in Molecular Medicine*, *22*(3), 190–199.
- 645 Kang, S. A., Jang, K. H., Seo, J. W., Kim, K. H., Kim, Y. H., Rairakhwada, D., & Rhee, S.
646 (2009). Levan: applications and perspectives. In: Rehm, B. H. A. (Eds.), *Microbial*
647 *production of biopolymers and polymer precursors* (pp. 145-161). Norfolk: Caister
648 Academic Press.

- 649 Kang, S. K., Park, S. J., Lee, J. D., & Lee, T. H. (2000). Physiological effects of
650 levanoligosaccharide on growth of intestinal microflora. *Journal of the Korean Society of*
651 *Food Science and Nutrition*, 29, 35-40
- 652 Keith, J., Wiley, B., Ball, D., Arcidiacono, S., Zorfass, D., Mayer, J., & Kaplan, D. (1991).
653 Continuous culture system for production of biopolymer levan using *Erwinia herbicola*.
654 *Biotechnology and Bioengineering*, 38(5), 557-560.
- 655 Kleessen, B., Schwarz, S., Boehm, A., Fuhrmann, H., Richter, A., Henle, T., & Krueger, M.
656 (2007). Jerusalem artichoke and chicory inulin in bakery products affect faecal microbiota
657 of healthy volunteers. *British Journal of Nutrition*, 98(3), 540-549.
- 658 Koenen, M. E., Rubio, J. M. C., Mueller, M. & Venema, K. (2016). The effect of agave
659 fructan products on the activity and composition of the microbiota determined in a
660 dynamic in vitro model of the human proximal large intestine. *Journal of Functional*
661 *Foods*, 22, 201-210.
- 662 Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber
663 to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell*, 165(6),
664 1332-1345.
- 665 Laparra, J. M., & Sanz, Y. (2010). Interactions of gut microbiota with functional food
666 components and nutraceuticals. *Pharmacological Research*, 61, 219-225.
- 667 Li, Y., & Triccas, J. A., & Ferenci, T. (1997). A novel levansucrase-levanase gene cluster in
668 *Bacillus stearothermophilus* ATCC12980. *Biochimica et Biophysica Acta (BBA) - Gene*
669 *Structure and Expression*, 1353, 203-208.
- 670 Lopez-Siles, M., Duncan, S. H., Garcia-Gil, L. J., & Martinez-Medina, M. (2017).
671 *Faecalibacterium prausnitzii*: From microbiology to diagnostics and prognostics. *ISME*
672 *Journal*, 11(4), 841-852.
- 673 Macfarlane, G. T., Macfarlane, S., & Gibson, G. R. (1998). Validation of a three-stage
674 compound continuous culture system for investigating the effect of retention time on the
675 ecology and metabolism of bacteria in the human colon. *Microbial Ecology*, 35, 180-187.
- 676 Manz, W., Amann, R., Ludwig, W., Vancanneyt, M., & Schleifer, K. H. (1996). Application
677 of a suite of 16S rRNA-specific oligonucleotide probes designed to investigate bacteria of
678 the phylum Cytophaga-Flavobacter-Bacteroides in the natural environment. *Microbiology*,
679 142, 1097-1106
- 680 Mardo, K., Visnapuu, T., Vijaet, H., Aasamets, A., Viigand, K., & Alama, T. (2017). A highly
681 active endo-levanase BT1760 of a dominant mammalian gut commensal *Bacteroides*
682 *thetaiotaomicron* cleaves not only various bacterial levans, but also levan of timothy grass,
683 *PLoS ONE*, 12, 1-26.
- 684 Martel, C. M., Warrilow, G. S., Jackson, C. J., Mullins, J. G. L., Togawa, R. C., & Parker, J.
685 E. (2010). Expression, purification and use of the soluble domain of *Lactobacillus paracasei*
686 β -fructosidase to optimise production of bioethanol from grass fructans. *Bioresource*
687 *Technology*, 101, 4395-4402.

- 688 Marx, S. P., Winkler, S., & Hartmeier, W. (2000). Metabolization of beta-(2, 6)-linked
689 fructose-oligosaccharides by different bifidobacteria. *FEMS microbiology letters*, *182*, 163–
690 169.
- 691 McBurney, M. I., Van Soest, P. J., & Jeraci, J. L. (1987). Colonic carcinogenesis: the
692 microbial feast or famine mechanism. *Nutrition and Cancer*, *10*, 23-28.
- 693 Meyer, D., & Stasse-Wolthuis, M. (2009). The bifidogenic effect of inulin and oligofructose
694 and its consequences for gut health. *European Journal of Clinical Nutrition*, *63(11)*, 1277–
695 1289.
- 696 Moens, F., & de Vuyst, L. (2017). Inulin-type fructan degradation capacity of clostridium
697 cluster IV and XIVa butyrate- producing colon bacteria and their associated metabolic
698 outcomes. *Beneficial Microbes*, *8(3)*, 473–490.
- 699 Moens, F., Weckx, S., & De Vuyst, L. (2016). Bifidobacterial inulin-type fructan degradation
700 capacity determines cross-feeding interactions between bifidobacteria and
701 *Faecalibacterium prausnitzii*. *International Journal of Food Microbiology*, *231*, 76–85.
- 702 Oliphant, K., & Allen-Vercoe, E. (2019). Macronutrient metabolism by the human gut
703 microbiome: major fermentation by-products and their impact on host health. *Microbiome*,
704 *7(91)*, 1-15.
- 705 Öner, E.T., Hernández, L., & Joan C. (2016). Review of Levan polysaccharide: From a
706 century of past experiences to future prospects. *Biotechnology Advances*, *34*, 827–844.
- 707 Ortiz-Soto, M. E., Porrás-Domínguez, J., Seibel, J., & López-Munguía, A. (2019). A close
708 look at the structural features and reaction conditions that modulate the synthesis of low
709 and high molecular weight fructans by levansucrases. *Carbohydrate Polymers*. *219*, 130-
710 142.
- 711 Patterson, J. K., Yasuda, K., Welch, R. M., Miller, D. D., & Lei, X. G. (2010). Supplemental
712 dietary inulin of variable chain lengths alters intestinal bacterial populations in young
713 pigs. *The Journal of nutrition*, *140*, 2158-2161.
- 714 Porrás-Domínguez, J. R., Avila-Fernandez, A., Rodríguez-Alegria, M. E., Miranda-Molina,
715 A., Escalante, A., & González-Cervantes, R. (2014). Levan-type FOS production using a
716 *Bacillus licheniformis* endolevanase. *Process Biochemistry*, *49*, 783–790.
- 717 Rakoff-Nahoum, S., Coyne, M. J., & Comstock, L. E. (2014). An ecological network of
718 polysaccharide utilization among human intestinal symbionts. *Current Biology*, *24(1)*, 40–
719 49.
- 720 Ramirez-Farias, C., Slezak, K., Fuller, Z., Duncan, A., Holtrop, G., & Louis, P. (2008). Effect
721 of inulin on the human gut microbiota: stimulation of *Bifidobacterium adolescentis* and
722 *Faecalibacterium prausnitzii*. *British Journal of Nutrition*, *101(04)*, 533.
- 723 Rastall, R. A., & Maitin, V. (2002). Prebiotics and synbiotics: towards the next generation.
724 *Current opinion in biotechnology*, *13*, 490-496.
- 725 Roberfroid, M. B. (2007). Inulin-type fructans: functional food ingredients. *The journal of*
726 *nutrition*, *137*, 2493-2502.
- 727 Roberfroid, M. B., Van Loo, F., & Gibson, G. R. (1998). The bifidogenic nature of chicory
728 inulin and oligofructose. *Journal of Nutrition*, *128*, 11-19.

- 729 Rumessen, J. J., Bode, S., Hamberg, O., & Gudmand-Hoyer, E. (1990). Fructans of
730 Jerusalem artichokes: intestinal transport, absorption, fermentation, and influence on blood
731 glucose, insulin, and C-peptide responses in healthy subjects. *The American Journal of*
732 *Clinical Nutrition*, *52*, 675-681.
- 733 Sarbini, S. R., Kolida, S., Naeye, T., Einerhand, A., Brison, Y., Remaud-Simeon, M., Monsan,
734 P., Gibson, G. R., & Rastall, R. A. (2011). *In vitro* fermentation of linear and alpha-1, 2-
735 branched dextrans by the human faecal microbiota. *Applied Environmental Microbiology*, *77*,
736 5307-5315.
- 737 Shoaib, M., Shehzad, A., Omar, M., Rakha, A., Raza, H., Sharif, H. R., ... Niazi, S.
738 (2016). Inulin: Properties, health benefits and food applications. *Carbohydrate Polymers*,
739 *147*, 444–454
- 740 Sghir, A, Chow, J. M., & Mackie, R. I. (1998). Continuous culture selection of bifidobacteria
741 and lactobacilli from human faecal samples using fructooligosaccharide as selective
742 substrate. *Journal of Applied Microbiology*, *85*, 769–777.
- 743 Sonnenburg, E. D., Zheng, H., Joglekar, P., Higginbottom, S. K., Firbank, S. J., & Bolam, D.
744 N. (2010). Specificity of polysaccharide use in intestinal bacteroides species determines
745 diet-induced microbiota alterations. *Cell*, *141*, 1241–1252.
- 746 Srikanth, R., Reddy, C. H. S. S. S., Siddartha, G., Ramaiah, M. J., & Uppuluri, K. B. (2015).
747 Review on production, characterization and applications of microbial levan. *Carbohydrate*
748 *Polymers*, *120*, 102–114.
- 749 Thøgersen, R., Castro-Mejía, J. L., Sundekilde, U. K., Hansen, L. H., Hansen, A. K., Nielsen,
750 D. S., & Bertram, H. C. (2018). Ingestion of an Inulin-Enriched Pork Sausage Product
751 Positively Modulates the Gut Microbiome and Metabolome of Healthy Rats. *Molecular*
752 *Nutrition & Food Research*, *13*, e1800608.
- 753 Thorasin, T., Hoyles, L., & McCartney, A. L. (2015). Dynamics and diversity of the
754 ‘*Atopobium* cluster’ in the human faecal microbiota, and phenotypic characterization of
755 ‘*Atopobium* cluster’ isolates. *Microbiology (United Kingdom)*, *161*(3), 565–579.
- 756 Tuohy, K. M., Finlay, R. K., Wynne, A. G., & Gibson, G. R. (2001). A Human Volunteer Study
757 on the Prebiotic Effects of HP-Inulin—Faecal Bacteria Enumerated Using Fluorescent *In*
758 *situ* Hybridisation (FISH). *Anaerobe*, *7*, 113-118.
- 759 Van der Beek, C. M., Canfora, E. E., Kip, A. M., Gorissen, S. H. M., Olde Damink, S. W.
760 M., van Eijk, H. M., ... Lenaerts, K. (2018). The prebiotic inulin improves substrate
761 metabolism and promotes short-chain fatty acid production in overweight to obese men.
762 *Metabolism*, *87*, 25–35.
- 763 Van de Wiele, T., Boon, N., Possemiers, S., Jacobs, H., & Verstraete, W. (2004) Prebiotic
764 effects of chicory inulin in the simulator of the human intestinal microbial ecosystem.
765 *FEMS Microbiology Ecology*, *51*, 143–153.

- 766 Van de Wiele, T., Boon, N., Possemiers, S., Jacobs, H., & Verstraete, W. (2007). Inulin-type
767 fructans of longer degree of polymerization exert more pronounced *in vitro* prebiotic effects.
768 *Journal of applied microbiology*, *102*, 452-460.
- 769 Walker, A. W., Duncan, S. H., Leitch, E. C. M., Child, M. W., & Flint, H. J. (2005). pH and
770 peptide supply can radically alter bacterial populations and short-chain fatty acid ratios
771 within microbial communities from the human colon. *Applied and environmental*
772 *microbiology*, *71*, 3692-3700.
- 773 Yong, J. G., Lee, J. H., & Hutkins, R. W. (2007). Functional analysis of the
774 fructooligosaccharide utilization operon in *Lactobacillus paracasei* 1195. *Applied and*
775 *environmental Microbiology*, *73*, 5716–5724.
- 776 Yoon, E. J., Yoo, S. H., Cha, J., & Gyu Lee, H. (2004). Effect of levan's branching structure
777 on antitumor activity. *International journal of biological macromolecules*, *34*, 191-194.